Clinical bottom line
Intranasal naloxone is an effective and practical option for opioid overdose reversal in prehospital settings, offering rapid administration without the need for intravenous access. Evidence supports its comparable efficacy to intramuscular and intravenous routes, with favorable safety and ease-of-use profiles that facilitate bystander and first-responder administration. Dose optimization remains an area of active investigation, with higher doses potentially improving outcomes in potent synthetic opioid overdoses. Intranasal naloxone is a critical tool in expanding access to lifesaving treatment amid the ongoing opioid crisis (Davis et al., 2014; Thompson et al., 2021).
What the evidence shows
Davis et al. (2014) conducted a systematic review confirming that intranasal naloxone effectively reverses opioid overdose symptoms in prehospital care, with success rates comparable to injectable formulations. The non-invasive route enables rapid deployment by laypersons and emergency medical services.
Robinson et al. (2014) reported that intranasal naloxone achieves adequate bioavailability and clinical efficacy, with minimal adverse effects, supporting its use as a first-line intervention in community and emergency settings.
Thompson et al. (2021) compared 0.4 mg versus 2 mg intranasal naloxone doses, finding that the higher dose improved reversal rates without increased adverse events, suggesting dose escalation may be beneficial in the context of potent synthetic opioids.
Venuso et al. (2025) provided a narrative review highlighting intranasal naloxone’s advantages, including ease of administration, rapid onset, and safety, while noting variability in dosing strategies and the need for standardized protocols.
Weaver et al. (2018) emphasized the role of pharmacists in facilitating naloxone access and education, underscoring intranasal formulations’ suitability for community distribution.
Ouyang et al. (2017) presented a case report illustrating successful bystander-administered intranasal naloxone reversal, demonstrating real-world applicability and potential to reduce mortality.
Caveats and uncertainty
Variability in intranasal naloxone formulations and dosing regimens complicates direct comparisons.
Intranasal absorption may be affected by nasal mucosa conditions, potentially reducing efficacy.
Repeated dosing or adjunctive injectable naloxone may be required in severe overdoses.
Limited data exist on intranasal naloxone efficacy specifically against highly potent synthetic opioids like fentanyl analogs.
Training and awareness among laypersons remain critical to optimize timely administration.
How this may change practice
Intranasal naloxone should be prioritized for distribution to first responders, community programs, and at-risk populations due to its ease of use and safety.
Higher-dose intranasal formulations may become standard to address evolving opioid potency.
Pharmacists and healthcare providers play key roles in education and expanding access.
Protocols should incorporate intranasal naloxone as a frontline intervention, with clear guidance on dosing and follow-up.
Ongoing surveillance and research are needed to refine dosing strategies and assess effectiveness against emerging synthetic opioids.